Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Lucintel | PRODUCT CODE: 1386505

Cover Image

PUBLISHER: Lucintel | PRODUCT CODE: 1386505

Mucopolysaccharidosis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4850
PDF (2 Users License)
USD 5800
PDF (5 Users License)
USD 6700
PDF (Corporate License)
USD 8850

Add to Cart

Mucopolysaccharidosis Treatment Trends and Forecast

The future of the global mucopolysaccharidosis treatment market looks promising with opportunities in the hospital and specialty clinic markets. The global mucopolysaccharidosis treatment market is expected to reach an estimated $4.2 billion by 2030 with a CAGR of 8.4% from 2024 to 2030. The major drivers for this market are increasing demand for effective treatments, rising prevalence of mucopolysaccharidosis, and rising healthcare spending.

A more than 150-page report is developed to help in your business decisions.

Mucopolysaccharidosis Treatment by Segment

The study includes a forecast for the global mucopolysaccharidosis treatment by type, treatment, end use, and region.

Mucopolysaccharidosis Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • MPS-I
  • MPS-II
  • MPS-IV
  • MPS-VI
  • MPS-VII
  • Others

Mucopolysaccharidosis Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Enzyme Replacement Therapy
  • Stem Cell Therapy

Mucopolysaccharidosis Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Others

Mucopolysaccharidosis Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Mucopolysaccharidosis Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies mucopolysaccharidosis treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the mucopolysaccharidosis treatment companies profiled in this report include-

  • Take da Pharmaceutical
  • BioMarin Pharmaceuticals
  • Ultragenyx Pharmaceutical
  • Sarepta Therapeutics
  • Abeona Therapeutics
  • Eloxx Pharmaceuticals
  • Esteve
  • Immusoft Corporation
  • Inventiva
  • GC Pharma

Mucopolysaccharidosis Treatment Market Insights

Lucintel forecasts that enzyme replacement therapy will remain the larger segment due to high demand from hospitals and clinics as it help to improve the symptoms and quality of life for MPS patients, and it can also extend their lifespan.

Within this market, hospitals will remain the largest segment over the forecast period due to it has the necessary infrastructure, such as specialized laboratories and equipment, and the necessary expertise like trained healthcare professionals, to provide MPS treatment.

North America will remain the largest segment due to high prevalence of MPS supported by well-established healthcare system and MPS reimbursement policy.

Features of the Global Mucopolysaccharidosis Treatment Market

Market Size Estimates: Mucopolysaccharidosis treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Mucopolysaccharidosis treatment market size by type, treatment, end use, and region in terms of value ($B).

Regional Analysis: Mucopolysaccharidosis treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, treatments, end uses, and regions for the mucopolysaccharidosis treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the mucopolysaccharidosis treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the mucopolysaccharidosis treatment market size?

Answer: The global mucopolysaccharidosis treatment market is expected to reach an estimated $4.2 billion by 2030.

Q.2 What is the growth forecast for mucopolysaccharidosis treatment market?

Answer: The global mucopolysaccharidosis treatment market is expected to grow with a CAGR of 8.4% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the mucopolysaccharidosis treatment market?

Answer: The major drivers for this market are increasing demand for effective treatments, rising prevalence of mucopolysaccharidosis and rising healthcare spending.

Q4. What are the major segments for mucopolysaccharidosis treatment market?

Answer: The future of the mucopolysaccharidosis treatment market looks promising with opportunities in the hospital and specialty clinic markets.

Q5. Who are the key mucopolysaccharidosis treatment market companies?

Answer: Some of the key mucopolysaccharidosis treatment companies are as follows:

  • Take da Pharmaceutical
  • BioMarin Pharmaceuticals
  • Ultragenyx Pharmaceutical
  • Sarepta Therapeutics
  • Abeona Therapeutics
  • Eloxx Pharmaceuticals
  • Esteve
  • Immusoft Corporation
  • Inventiva
  • GC Pharma

Q6. Which mucopolysaccharidosis treatment market segment will be the largest in future?

Answer: Lucintel forecasts that enzyme replacement therapy will remain the larger segment due to high demand from hospitals and clinics as it help to improve the symptoms and quality of life for MPS patients, and it can also extend their lifespan.

Q7. In mucopolysaccharidosis treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment due to high prevalence of MPS supported by well-established healthcare system and MPS reimbursement policy.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the mucopolysaccharidosis treatment market by type (MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, and others), treatment (enzyme replacement therapy and stem cell therapy), end use (hospitals, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Mucopolysaccharidosis Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Mucopolysaccharidosis Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Mucopolysaccharidosis Treatment Market by Type
    • 3.3.1: MPS-I
    • 3.3.2: MPS-II
    • 3.3.3: MPS-IV
    • 3.3.4: MPS-VI
    • 3.3.5: MPS-VII
    • 3.3.6: Others
  • 3.4: Global Mucopolysaccharidosis Treatment Market by Treatment
    • 3.4.1: Enzyme Replacement Therapy
    • 3.4.2: Stem Cell Therapy
  • 3.5: Global Mucopolysaccharidosis Treatment Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Specialty Clinics
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Mucopolysaccharidosis Treatment Market by Region
  • 4.2: North American Mucopolysaccharidosis Treatment Market
    • 4.2.2: North American Mucopolysaccharidosis Treatment Market by End Use: Hospitals, Specialty Clinics, and Others
  • 4.3: European Mucopolysaccharidosis Treatment Market
    • 4.3.1: European Mucopolysaccharidosis Treatment Market by Treatment: Enzyme Replacement Therapy and Stem Cell Therapy
    • 4.3.2: European Mucopolysaccharidosis Treatment Market by End Use: Hospitals, Specialty Clinics, and Others
  • 4.4: APAC Mucopolysaccharidosis Treatment Market
    • 4.4.1: APAC Mucopolysaccharidosis Treatment Market by Treatment: Enzyme Replacement Therapy and Stem Cell Therapy
    • 4.4.2: APAC Mucopolysaccharidosis Treatment Market by End Use: Hospitals, Specialty Clinics, and Others
  • 4.5: ROW Mucopolysaccharidosis Treatment Market
    • 4.5.1: ROW Mucopolysaccharidosis Treatment Market by Treatment: Enzyme Replacement Therapy and Stem Cell Therapy
    • 4.5.2: ROW Mucopolysaccharidosis Treatment Market by End Use: Hospitals, Specialty Clinics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Mucopolysaccharidosis Treatment Market by Type
    • 6.1.2: Growth Opportunities for the Global Mucopolysaccharidosis Treatment Market by Treatment
    • 6.1.3: Growth Opportunities for the Global Mucopolysaccharidosis Treatment Market by End Use
    • 6.1.4: Growth Opportunities for the Global Mucopolysaccharidosis Treatment Market by Region
  • 6.2: Emerging Trends in the Global Mucopolysaccharidosis Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Mucopolysaccharidosis Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Mucopolysaccharidosis Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Take da Pharmaceutical
  • 7.2: BioMarin Pharmaceuticals
  • 7.3: Ultragenyx Pharmaceutical
  • 7.4: Sarepta Therapeutics
  • 7.5: Abeona Therapeutics
  • 7.6: Eloxx Pharmaceuticals
  • 7.7: Esteve
  • 7.8: Immusoft Corporation
  • 7.9: Inventiva
  • 7.10: GC Pharma
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!